James Song, MD, FAAD

James Song, MD, FAAD, discusses how improving patient adherence to atopic dermatitis treatments requires addressing barriers such as cost, treatment complexity, and patient education, while highlighting how emerging therapies and simplified regimens may help overcome these challenges in the future.

A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations.

James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.

James Song, MD, discusses how Janus kinase (JAK) inhibitors represent a breakthrough in vitiligo treatment by effectively targeting the immune pathways responsible for depigmentation, offering patients a powerful new therapeutic option with promising repigmentation results.

James Song, MD, discusses how recent advances in vitiligo treatment, including Janus kinase inhibitors and targeted immunotherapies, are transforming the therapeutic landscape with more effective options for repigmentation and disease management.

Song shared top clinical tips at Fall Clinical, covering alopecia areata, refractory dermatoses, and novel non-steroidal topicals.

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.

James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.

An expert in dermatology presents the case of a 23-year-old male patient presenting with unstable vitiligo. He delves into treatment options available for managing this condition, shedding light on the nuances and optimal scenarios for each therapeutic agent.

James Song, MD, FAAD, presents the case of a 14-year-old male patient seeking vitiligo treatment. He emphasizes the significance of addressing mental health concerns alongside managing the physical symptoms of this condition. He further discusses possible approaches to treat the patient's depigmented patches, particularly considering that this patient was diagnosed with segmental vitiligo.